19 citations
,
March 1994 in “Fertility and sterility” The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
53 citations
,
October 2012 in “The FASEB Journal” Bimatoprost, a glaucoma medication, may also help treat hair loss.
81 citations
,
August 2011 in “Journal of The American Academy of Dermatology” Latanoprost 0.1% may effectively treat hair loss.
14 citations
,
August 2018 in “Journal of Pharmaceutical and Biomedical Analysis” 1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
August 2024 in “JEADV Clinical Practice” Mesotherapy with dutasteride improves hair growth and reduces symptoms in frontal fibrosing alopecia.
January 2024 in “Case Reports in Endocrinology” Cortisone tapering may help improve severe myasthenia gravis and alopecia areata after thymectomy.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
3 citations
,
December 2015 in “Musculoskeletal care” Many patients on methotrexate experience significant side effects but still continue the medication.
28 citations
,
March 2018 in “Archives of Dermatological Research” March 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” Topical finasteride didn't significantly reduce facial hair, but patients felt it helped.
1 citations
,
January 1979 in “International Journal of Dermatology” Cyproterone acetate effectively treats hirsutism and related conditions.
6 citations
,
January 1977 in “Archives of dermatological research”
82 citations
,
August 2006 in “Pharmacology, Biochemistry and Behavior” Certain steroids in the brain affect mood and symptoms of depression, and treatments targeting these steroids show promise for improving these symptoms.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
December 2022 in “Jurnal Farmasi Klinik Base Practice” Cyclophosphamide helped 59.4% of children with steroid-resistant nephrotic syndrome but caused side effects in 40.6%.
September 2023 in “Pharmaceuticals” Tiny particles improved delivery of hair loss treatments to hair follicles, with lipid-based particles performing best.
12 citations
,
September 2021 in “Journal of molecular structure” The MXD/24HA salt is more effective for hair growth than raw MXD.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
17 citations
,
March 2004 in “Journal of Investigative Dermatology” Soymetide-4 from soy can prevent hair loss caused by a cancer drug in rats.
3 citations
,
January 2018 in “Archives of Disease in Childhood” Switching to generic tacrolimus was safe, effective, and saved money.
5 citations
,
October 2018 in “Journal of Cosmetic Dermatology” Oral pulse steroids reduce TNF-α levels, improving alopecia areata.
Microneedling with Triamcinolone acetonide is an effective, less invasive, and safe alternative to direct injections for treating alopecia areata.
December 2024 in “PubMed” Cyclosporine effectively treated a woman's stubborn skin condition.
75 citations
,
November 2007 in “Clinical endocrinology” Certain medications including flutamide, spironolactone, and others effectively reduce excessive hair growth in women, especially when combined with lifestyle changes.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.